The analysis of cannabinoids in e-cigarette liquids using LC-HRAM-MS and LC-UV.


Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
15 Jun 2023
Historique:
received: 10 02 2023
revised: 11 04 2023
accepted: 11 04 2023
medline: 5 5 2023
pubmed: 17 4 2023
entrez: 16 4 2023
Statut: ppublish

Résumé

The use of cannabidiol or CBD products has skyrocketed in the last five years due to the alleged therapeutic benefits, a low potential for abuse and lack of the typical psychoactive effects associated with the use of cannabis products containing high levels of ∆9-tetrahydrocannabinol (∆9-THC). In Belgium, CBD-containing e-liquids with a total THC content lower than 0.2% (w/w) are currently legal. In order to verify the compliance of the different CBD-containing e-cigarette liquids that are available to the Belgian population, a method was developed for screening of 17 cannabinoids and to quantify the major cannabinoids such as CBD, CBDA, ∆9-THC and ∆9-THCA. The latter was fully validated using the 'total error' approach, applying accuracy profiles and conforming to ISO17025. None of the analysed samples exceeded the legal limit for the total amount of ∆9-THC present. However, of the 20 CBD-liquids investigated in this study, only 30% of the samples contained an amount of CBD that was within 10% deviation of the label claim. Moreover, the CBD e-liquids labelled "full/broad spectrum" consisted of several minor alkaloids in comparison to the "classic" CBD e-liquids where the acidic forms of the cannabinoids were not present. Currently, no legislation is available for the regulation of CBD e-liquids, however these results indicate that quality controls are pertinent especially concerning the discrepancy in CBD label accuracy.

Identifiants

pubmed: 37062207
pii: S0731-7085(23)00163-2
doi: 10.1016/j.jpba.2023.115394
pii:
doi:

Substances chimiques

Cannabinoids 0
Cannabidiol 19GBJ60SN5
Dronabinol 7J8897W37S

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115394

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sophia Barhdadi (S)

Department of Chemical and Physical Health Risks, Medicines and Healthcare Products, Sciensano, J. Wytsmansstraat 14, B-1050 Brussels, Belgium. Electronic address: sophia.barhdadi@sciensano.be.

Patricia Courselle (P)

Department of Chemical and Physical Health Risks, Medicines and Healthcare Products, Sciensano, J. Wytsmansstraat 14, B-1050 Brussels, Belgium.

Eric Deconinck (E)

Department of Chemical and Physical Health Risks, Medicines and Healthcare Products, Sciensano, J. Wytsmansstraat 14, B-1050 Brussels, Belgium.

Celine Vanhee (C)

Department of Chemical and Physical Health Risks, Medicines and Healthcare Products, Sciensano, J. Wytsmansstraat 14, B-1050 Brussels, Belgium.

Articles similaires

Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization.

Kelly C Young-Wolff, Natalie E Slama, Lyndsay A Avalos et al.
1.00
Humans Female Pregnancy California Adult
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics
Humans Smoking Cessation England Middle Aged Male
Humans Pisum sativum Breast Neoplasms Tandem Mass Spectrometry Plant Extracts

Classifications MeSH